Safety Profile of Baricitinib For the Treatment of Rheumatoid Arthritis Over a Median of 3 Years of Treatment: An Updated Integrated Safety Analysis
Lancet Rheumatol 2020;2:e347–57
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Lancet Rheumatol 2020;2:e347–57
Clin Exp Rheumatol . Jul-Aug 2020;38(4):732-741. Epub 2020 May 20.
Arthritis Rheumatol. 2020 Sep; 72(9): 1435–1446.
RMD Open 2020;6:e001095
Drug Saf. 2020;43:379-392
Z Rheumatol. 2020 DOI: 10.1007/s00393-020-00750-1
Ann Rheum Dis. 2020 10.1136/annrheumdis-2019-216566
Intern Med. 2020;59(6):817-821
JAMA Dermatol 2020;156:649–58. doi 10.1001/jamadermatol.2020.0723
Blauvelt et al. shows superior and sustained efficacy for risankizumab in maintaining skin clearance over time versus placebo upon withdrawal, alongside a favourable safety profile in chronic plaque psoriasis through a phase 3, randomised, double-blind, placebo-controlled study, assessing PASI 90 and sPGA score of 0/1 at Week 16.
Ther Adv Musculoskelet Dis. 2020;12:1759720X19899296